Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer

Rhea-AI Summary

Defence Therapeutics (OTCQB: DTCFF) has announced progress in its cancer therapy programs utilizing its proprietary Accum® technology in both Antibody Drug Conjugates (ADCs) and radiopharmaceuticals. The company's Accum®-based ADCs have shown enhanced efficacy in preclinical cancer models compared to conventional ADCs.

Defence is conducting studies through the Canadian Nuclear Laboratories under the CNRI-H program, focusing on biodistribution, pharmacokinetic profiles, and therapeutic potency. The company operates primarily from its Montreal laboratory while planning U.S. expansion. The target markets show significant potential, with the global ADC market projected to reach $29.9 billion by 2034 (9.23% CAGR) and the radiopharmaceutical market expected to hit $16.87 billion by 2033 (9.9% CAGR).

Positive

• Preclinical studies show enhanced efficacy of Accum®-based ADCs compared to conventional ADCs
• Ongoing collaborations with ADC companies for potential licensing deals
• Received CNRI-H program grant for radiopharmaceutical studies
• Operating in rapidly growing markets with strong CAGR projections

Negative

• Studies and optimizations still ongoing with no completed results yet
• No confirmed partnerships or licensing deals at present

Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that its highly impactful programs on ADC and Radiopharma programs, which includes collaborations and preclinical studies on cancer therapies with Accum^® are ongoing.

Defence's Accum^®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs. Defence continues to advance studies that validate additional Accum^®-based ADCs, including optimization to increase the value and to attract Pharmaceuticals and Biotech companies for potential licensing deals and co-development opportunities. In addition, collaborations and preclinical studies with ADCs companies are ongoing to validate and confirm the significant efficacy improvement when Defence's Accum^® technology is added to their respective ADC.

Defence's Radiopharma focused program continues to enhance the optimization of Accum^® radiolabelling with studies performed by the Canadian Nuclear Laboratories ("CNL") under notably the CNRI-H program that Defence was granted. The complete study is being performed, including biodistribution, pharmacokinetic profile and therapeutic potency, using radiolabelled Accum^® with selected antibodies. Defence's scientific team is confident that the addition of the Accum^® technology being applied in the radiopharmaceuticals industry may be transformative.

The global antibody drug conjugate (ADC) market size is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2034. The global radiopharmaceutical market is projected to reach $16.87-billion (U.S.) by 2033, growing at a CAGR of 9.9% during the forecast period (2025-2033).
https://www.towardshealthcare.com/insights/antibody-drug-conjugate-market-sizing
https://straitsresearch.com/report/radiopharmaceutical-market

Defence's Accum^® technology optimization is also currently ongoing, with more detail to be released upon completion of all the studies related.

The Company will announce key results when they become available and completed as well as details on partnerships when and if deals and licensing occurred. Defence continues to work on studies in Canada, mainly at Defence's laboratory located in Montreal, Canada and in parallel the Company continues pursuing its plan to expand its presence to the US.

About Defence:

Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM^® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.

For further information:
Sebastien Plouffe, Founder, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258655

FAQ

What is the market potential for Defence Therapeutics (DTCFF) ADC technology?

The global ADC market is projected to grow from $13.51 billion in 2025 to $29.9 billion by 2034, with a CAGR of 9.23%.

How does Defence Therapeutics' Accum® technology improve cancer treatments?

Accum®-based ADCs have demonstrated enhanced intracellular delivery and improved cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs.

What partnerships does Defence Therapeutics have for its Accum® technology?

Defence is currently conducting collaborations and preclinical studies with ADC companies to validate efficacy improvements, with potential licensing deals and co-development opportunities under discussion.

What is the projected growth of the radiopharmaceutical market that Defence Therapeutics is targeting?

The global radiopharmaceutical market is expected to reach $16.87 billion by 2033, growing at a CAGR of 9.9% during 2025-2033.

Where is Defence Therapeutics conducting its research studies?

Defence conducts studies primarily at its laboratory in Montreal, Canada, and through the Canadian Nuclear Laboratories (CNL), with plans to expand presence to the US.